Physician profile
Matthew J Windrow
NPI 1487673935
$120,267.35
in general payments reported to CMS, 2019-2025
38 companies · $999 in 2025
The $999 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $16K · 2021: $31K · 2022: $27K · 2023: $21K · 2024: $1,639 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $3,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,300.00 |
| Food and Beverage | $3,502.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $115,632.61 | 2019-2025 | Allocate, Senza |
| Abbvie INC. | $1,232.28 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $649.41 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $547.77 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $330.29 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Lilly USA, LLC | $215.62 | 2022-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $171.85 | 2023-2025 | Rexulti |
| Averitas Pharma INC. | $153.22 | 2024-2025 | Qutenza |
| Glaxosmithkline, LLC. | $126.98 | 2020-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Supernus Pharmaceuticals, INC. | $117.63 | 2022-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $116.71 | 2024-2025 | Austedo Xr, Uzedy |
| Amgen INC. | $114.71 | 2022-2024 | Repatha, Otezla, Evenity |
| Pfizer INC. | $91.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $76.55 | 2023-2024 | |
| Astellas Pharma US INC | $75.83 | 2023-2024 | Veozah |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Windrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.